Borja Puertas, Beatriz Rey-Búa, R. Eiros, Alberto Martín-Arribas, E. Montero-Mateos, A. Hernandez-Sanchez, S. Gómez-Úbeda, Elena Alejo-Alonso, Ana A. Martín-López, P. Antunez, Eduardo Villacorta-Argüelles, M. Gallego-Delgado, N. Puig, M. Mateos, V. González-Calle
{"title":"Case Report: Renal relapse after heart transplantation, induction, and autologous stem cell transplantation in a patient with AL amyloidosis with exclusive cardiac involvement","authors":"Borja Puertas, Beatriz Rey-Búa, R. Eiros, Alberto Martín-Arribas, E. Montero-Mateos, A. Hernandez-Sanchez, S. Gómez-Úbeda, Elena Alejo-Alonso, Ana A. Martín-López, P. Antunez, Eduardo Villacorta-Argüelles, M. Gallego-Delgado, N. Puig, M. Mateos, V. González-Calle","doi":"10.3389/frhem.2022.997262","DOIUrl":"https://doi.org/10.3389/frhem.2022.997262","url":null,"abstract":"There is no recommendation on what salvage therapy is optimal in the solid organ recipient with AL amyloidosis, such as a heart transplant. With this case, we illustrate how treatment with daratumumab may be effective and safe in a patient with AL amyloidosis with renal involvement at the relapse after heart transplantation and autologous stem cell transplantation.","PeriodicalId":101407,"journal":{"name":"Frontiers in hematology","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129291282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marwa Elsayed, Haitham Abdelhakim, L. Shune, S. Abhyankar, Anurag K. Singh, Da Zhang, J. McGuirk, O. Aljitawi
{"title":"Case Report: Unique patterns of lymphocyte recovery post-hematopoietic stem cell transplant associated with hyperbaric oxygen therapy: A case series","authors":"Marwa Elsayed, Haitham Abdelhakim, L. Shune, S. Abhyankar, Anurag K. Singh, Da Zhang, J. McGuirk, O. Aljitawi","doi":"10.3389/frhem.2022.1008363","DOIUrl":"https://doi.org/10.3389/frhem.2022.1008363","url":null,"abstract":"The utilization of hematopoietic stem cell transplantation (HSCT) has been rapidly growing due to multiple factors, including better availability of donors and improved supportive care. Hyperbaric oxygen has been associated with the improvement of hematopoietic stem cell (HSC) homing at the time of transplant through lowering erythropoietin levels in preclinical studies. We studied the role of hyperbaric oxygen (HBO) in the enhancement of engraftment of HSC when utilized prior to umbilical cord HSCT and autologous HSCT in two pilot clinical trials with excellent safety profiles. In these two pilot studies, we observed an uncommon phenomenon post-transplant, particularly a significant peripheral blood lymphocytosis and lymphocyte infiltration of different tissues in 3/34 of HBO-treated patients. This peripheral blood lymphocyte expansion was associated with various clinical manifestations that can be confused with infections, inflammatory conditions, or disease relapse. We hypothesize that this observation is related to different immune reconstitution dynamics related to the use of HBO. While the incidence is ~9%, this may have implications as HBO is being investigated in larger clinical trials. This case series highlights the clinical presentation, course, outcome, and potential implications of this significant rise in lymphocytes when utilizing HBO before HSCT.","PeriodicalId":101407,"journal":{"name":"Frontiers in hematology","volume":"57 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134302936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yueh-Shih Chang, Jung-Jr Ye, Tzu-Chien Cheng, Yingfen Wen, Chi-Ying F. Huang, K. Yeh
{"title":"Case report: Reactive Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis and thrombosis with thrombocytopenia syndrome following SARS-CoV-2 vaccination and treated with intravenous immunoglobulin","authors":"Yueh-Shih Chang, Jung-Jr Ye, Tzu-Chien Cheng, Yingfen Wen, Chi-Ying F. Huang, K. Yeh","doi":"10.3389/frhem.2022.983424","DOIUrl":"https://doi.org/10.3389/frhem.2022.983424","url":null,"abstract":"Viral reactivation was previously reported after severe acute respiratory syndrome coronavirus‐2 (SARS-CoV-2) infection but was seldom documented after SARS-CoV-2 vaccination, except varicella-zoster virus and cytomegalovirus. Here, we present a case of reactive Epstein–Barr virus (EBV)-associated hemophagocytic lymphohistiocytosis (HLH) and thrombosis with thrombocytopenia syndrome after receiving SARS-CoV-2 mRNA vaccination. Antiplatelet factor 4 antibody was detected, and the bone marrow study showed hemophagocytosis and was positive in the immunohistochemistry staining for EBV-encoded small nuclear RNAs and negative staining for CD3 and CD56 markers of small lymphocytes. The high percentage of CD38 high/HLA-DR+ cells among CD8+ T cells further confirmed HLH. After intravenous administration of immunoglobulin, the clinical symptoms, D-dimer level, fibrinogen, platelet count, EBV-DNA titer, and anti-PF4 level were all improved. Further investigation into the pathogenesis of vaccine-associated EBV reactivation, such as TNF-α, interleukin-1β (IL-1β), and interleukin-6 (IL-6), is warranted.","PeriodicalId":101407,"journal":{"name":"Frontiers in hematology","volume":"70 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123223490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Troiano, V. Brescia, Lucia De Marinis, A. Marinaccio, R. Lovero, R. Rizzi, F. Di Serio
{"title":"Case Report: A case of IgD lambda/lambda Multiple Myeloma in patient with acute renal failure and without monoclonal spike in serum electrophoresis","authors":"T. Troiano, V. Brescia, Lucia De Marinis, A. Marinaccio, R. Lovero, R. Rizzi, F. Di Serio","doi":"10.3389/frhem.2022.974392","DOIUrl":"https://doi.org/10.3389/frhem.2022.974392","url":null,"abstract":"Background IgD Multiple Myeloma is a rare form of plasma cell dyscrasia and accounts for approximately 1-2% of all cases of Multiple Myeloma. It mainly affects young, male subjects; it is characterized by an aggressive course, a high production of Bence Jones protein, acute renal failure and an often unfortunate outcome compared to the other isotypes of MM. A distinctive feature is the lack of a monoclonal peak on serum protein electrophoresis (SPE). Case report a 57-year-old man with pain in his left lower limb and weight loss goes to the Emergency Department (Emergency Department). Laboratory tests performed showed normocytic normochromic anemia (Hemoglobin 9.4 g/dL), acute renal failure (s-creatinine 2.85 mg/dL, e-GFR 23 mL/min/1.73 m². serum protein electrophoresis (SPE) detected only mild polyclonal in the gamma zone with no evidence of any monoclonal peak. Results serum immunofixation (s-IFE) showed a monoclonal IgD λ band and a monoclonal λ band. The Free Light Chains (s-FLC) measurement showed a ratio of 0.04. The bone marrow biopsy confirmed an infiltration of> 20% of clonal plasma cells; renal biopsy diagnosed “cast nephropathy”. Conclusion IgD λ/λ Multiple Myeloma is a rare form of this disease with a poor prognosis; an early and correct laboratory diagnosis is crucial for appropriate treatment and effective monitoring in order to improve patient outcome.","PeriodicalId":101407,"journal":{"name":"Frontiers in hematology","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127684241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}